10.1016/j.coph.2011.05.008
10.1016/j.coph.2011.05.008
The continuing evolution of the drug discovery process in the pharmaceutical industry
10.1016/s0014-827x(01)01019-9 · 2001
Modern drug discovery process: An in silico approach
2011
10.1124/pr.112.007336
10.1124/pr.112.007336
10.1016/s0165-6147(00)01584-4
10.1016/s0165-6147(00)01584-4
Current trends in ligand-based virtual screening: molecular representations, data mining methods, new application areas, and performance evaluation
10.1021/ci900419k · 2010
The process of structure-based drug design
10.1016/j.chembiol.2003.09.002 · 2003
10.1021/jm501535r
10.1021/jm501535r
Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges
10.2165/00003088-200342060-00002 · 2003
Optimization of metabolic stability as a goal of modern drug design
10.1002/med.1017 · 2001
Cytochromes P450: a success story
10.1186/gb-2000-1-6-reviews3003 · 2000
10.1089/ars.2010.3109
10.1089/ars.2010.3109
Prediction and analysis of the modular structure of cytochrome P450 monooxygenases
10.1186/1472-6807-10-34 · 2010
Unresolved referenced work
Kept as external metadata until matched
Predicting mouse liver microsomal stability with “pruned” machine learning models and public data
10.1007/s11095-015-1800-5 · 2016
Addressing the metabolic stability of antituberculars through machine learning
10.1021/acsmedchemlett.7b00299 · 2017
MetStabOn-online platform for metabolic stability predictions
10.3390/ijms19041040 · 2018
How can SHAP values help to shape metabolic stability of chemical compounds?
10.1186/s13321-021-00542-y · 2021
Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches
10.2174/138920010791514306 · 2010
QSPR studies on aqueous solubilities of drug-like compounds
10.3390/ijms10062558 · 2009
Current mathematical methods used in QSAR/QSPR studies
10.3390/ijms10051978 · 2009
Estimation of the aqueous solubility of organic molecules by the group contribution approach
10.1021/ci000152d · 2001
Prediction of aqueous solubility of a diverse set of compounds using quantitative structure-property relationships
10.1021/jm020266b · 2003
10.1021/ci034184n
10.1021/ci034184n
In silico prediction of blood brain barrier permeability: an artificial neural network model
10.1021/ci050303i · 2006
QSAR-based permeability model for drug-like compounds
10.1016/j.bmc.2011.03.011 · 2011
BioPPSy: an open-source platform for QSAR/QSPR analysis
10.1371/journal.pone.0166298 · 2016
QSPR/QSAR: state-of-art, weirdness, the future
10.3390/molecules25061292 · 2020
Unresolved referenced work
Kept as external metadata until matched
MoleculeNet: a benchmark for molecular machine learning
10.1039/c7sc02664a · 2017
A multitask GNN-based interpretable model for discovery of selective JAK inhibitors
10.1186/s13321-022-00593-9 · 2022
ADMET Evaluation in Drug Discovery. 19. Reliable Prediction of Human Cytochrome P450 Inhibition Using Artificial Intelligence Approaches
10.1021/acs.jcim.9b00801 · 2019
10.1021/acs.molpharmaceut.8b00110
10.1021/acs.molpharmaceut.8b00110
10.1021/acs.jcim.9b01202
10.1021/acs.jcim.9b01202
Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds
10.1002/minf.202000028 · 2020
ChEMBL: a large-scale bioactivity database for drug discovery
10.1093/nar/gkr777 · 2011
10.1126/science.1099736
10.1126/science.1099736
Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid
10.1074/jbc.m802180200 · 2008
Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site
10.1074/jbc.m312516200 · 2004
10.1016/j.drudis.2014.03.012
10.1016/j.drudis.2014.03.012
